UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1167-14
Program Prior Authorization/Notification
Medication Entresto® (valsartan-sacubitril)
P&T Approval Date 5/2015, 6/2016, 6/2017, 6/2018, 6/2019, 11/2019, 4/2020, 4/2021, 4/2022,
4/2023, 4/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Entresto (valsartan-sacubitril) is indicated to reduce the risk of cardiovascular death and
hospitalization for heart failure patients with chronic heart failure. Benefits are most clearly
evident in patients with left ventricular ejection fraction (LVEF) below normal. It is also
indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic
dysfunction in pediatric patients aged one year and older.
2. Coverage Criteriaa:
A. Authorization
1. Entresto will be approved based on one of the following:
a. Diagnosis of chronic adult heart failure
-OR-
b. Diagnosis of pediatric heart failure with systemic left ventricular systolic dysfunction
which is symptomatic.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply Limits may be in place.
4. References:
1. Entresto [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April
2024.
Program Prior Authorization/Notification - Entresto (valsartan-sacubitril)
Change Control
5/2015 New program.
10/2015 Administrative change to adjust program number.
6/2016 Updated reference.
6/2017 Annual review. No changes.
6/2018 Annual review. Updated reauthorization approval time period.
12/2018 Administrative change to add statement regarding use of automated
processes.
6/2019 Annual review. Removed reauthorization criteria.
11/2019 Added criteria for coverage of pediatric heart failure. Updated references.
4/2020 Administrative update to remove “initial” from authorization criteria.
4/2021 Updated to remove heart failure classification and ejection fraction
requirements based on updated labeling.
4/2022 Annual review with no changes.
4/2023 Annual review. Added state mandate footnote.
4/2024 Annual review with no changes.
5/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2